

<h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>		Application number	10/574,560					
		Filing date	1 February 2007					
		First Named Inventor	Serdar SEL et al					
		Art Unit	1635					
		Examiner name	Bowman, A					
		Attorney Docket Number	23593					
U.S. PATENTS								
Ex. Initials	Cite No.	Patent Number	Kind Code					
/AB/	1	7355035						
	2							
	3							
	4							
	5							
U.S. PATENT APPLICATION PUBLICATIONS								
Ex. Initials	Cite No.	Publication Number	Kind Code					
	1							
	2							
	3							
FOREIGN PATENT DOCUMENTS								
Ex. Initials	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where Relevant Passages or relevant Figs. appear	Transl.?
/AB/	1	WO 00/51621			8 Sept. 2000	Epigenesis Pharm		
/AB/	2	WO 01/11023			15 Feb. 2001	Johnson & Johnson		
	3							
	4							
NON-PATENT LITERATURE								
Ex. Initials	Cite No.	AUTHOR NAME, Article Title, Book Title, Date, Page(s), Vol/Iss. No., Publisher, City/Country						
/AB/	1	Santoro S W et al; A general purpose RNA-cleaving ...; Nat. Acad. Sci., Vol. 94, April 1997; pgs. 4262-4266						
/AB/	2	Sun L Q et al; Catalytic nucleic acids ...; Pharma. Review; Williams & Wilkins Inc.; Sept. 2000; pgs. 325-347						
/AB/	3	Imagawa S et al; Negative regulation of the erythropoietin ...; Blood, W.B. Saunders; Feb. 1997; pgs. 1430 - 1439						
EXAMINER SIGNATURE								
Examiner Signature	/Amy Bowman/	Date Considered	06/06/2011					

14 January 2011

KF Ross PC
Customer Number: 535
5683 Riverdale Ave. Box 900
Bronx (Riverdale), NY 10471
23593PTOSB81.WPD